Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NewGenIvf Group Limited Class A Ordinary Shares (NIVF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: NIVF (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 2.67% | Avg. Invested days 206 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.43M USD | Price to earnings Ratio 3.58 | 1Y Target Price - |
Price to earnings Ratio 3.58 | 1Y Target Price - | ||
Volume (30-day avg) 1780817 | Beta -0.3 | 52 Weeks Range 0.86 - 211.66 | Updated Date 03/27/2025 |
52 Weeks Range 0.86 - 211.66 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.42% | Operating Margin (TTM) 14.69% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 3.58 | Forward PE - | Enterprise Value 5186554 | Price to Sales(TTM) 0.96 |
Enterprise Value 5186554 | Price to Sales(TTM) 0.96 | ||
Enterprise Value to Revenue 1.01 | Enterprise Value to EBITDA 13.5 | Shares Outstanding 5066020 | Shares Floating 558481 |
Shares Outstanding 5066020 | Shares Floating 558481 | ||
Percent Insiders 2.24 | Percent Institutions 1.31 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NewGenIvf Group Limited Class A Ordinary Shares
Company Overview
History and Background
NewGenIvf Group Limited is a fertility treatment provider. Founded to deliver high-quality IVF services.
Core Business Areas
- Fertility Clinics: Operates fertility clinics offering a range of assisted reproductive technologies (ART), including in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT).
- Andrology Services: Provides andrology services, including semen analysis, sperm preparation, and sperm freezing.
- Embryology Services: Offers embryology services, including embryo culture, embryo grading, and embryo cryopreservation.
Leadership and Structure
Details on leadership and organizational structure are publicly available through investor relations and corporate governance disclosures.
Top Products and Market Share
Key Offerings
- IVF Treatments: The primary service offering, utilizing advanced techniques for fertilization. Limited publicly available data on market share. Competitors include other IVF clinics and fertility centers.
- ICSI: Intracytoplasmic Sperm Injection is another procedure offered by NewGenIvf Group Limited. Limited public market share data. Similar competitors as IVF.
Market Dynamics
Industry Overview
The fertility industry is growing, driven by factors such as declining fertility rates, advancements in ART, and increasing awareness of fertility treatments.
Positioning
NewGenIvf Group Limited competes with other fertility clinics and centers in specific geographic regions.
Total Addressable Market (TAM)
The global fertility services market is expected to reach billions of dollars. NewGenIvf Group Limited captures a portion of this market through its clinic network.
Upturn SWOT Analysis
Strengths
- Experienced medical professionals
- Advanced technology adoption
- Strong brand reputation in specific markets
Weaknesses
- Geographic concentration
- Dependence on specific regions
- Limited market share compared to larger players
Opportunities
- Expansion into new geographic markets
- Development of new fertility treatment technologies
- Partnerships with healthcare providers
Threats
- Increased competition
- Changes in regulations
- Economic downturns affecting patient affordability
Competitors and Market Share
Key Competitors
- FERT
- COLC
- CRTX
Competitive Landscape
NewGenIvf Group Limited's competitive advantages depend on its specific clinics and services. Requires more granular data on each geographic market to evaluate
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would be based on past financial performance and market expansion. Direct data not provided.
Future Projections: Future growth projections are based on analyst estimates and market trends. Details not provided.
Recent Initiatives: Recent strategic initiatives would include clinic expansions, technology upgrades, and marketing efforts. Details not provided.
Summary
NewGenIvf Group Limited is a smaller player in the fertility market, with potential for growth through geographic expansion and technology adoption. It faces competition from larger, established firms and must navigate regulatory challenges and economic fluctuations. The financial health depends on clinic performance and strategic management. Investing in new technologies and expansion strategies is crucial for future growth and competitive advantage.
Similar Companies
- FERT
- COLC
- CRTX
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- SEC Filings (if applicable for publicly traded companies listed above as competitors). Publicly available data
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewGenIvf Group Limited Class A Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-04-03 | Co-Founder, Chairman & CEO Mr. Wing Fung Siu | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 70 | Website https://newgenivf.com |
Full time employees 70 | Website https://newgenivf.com | ||
NewGenIvf Group Limited provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, and Kyrgyzstan. Its services includes mitochondrial replacement (MRT) therapy in reproductive, intrauterine insemination, mrt techniques, in-vitro fertilization /ICSI, hysteroscopy, semen analysis, TESE/TESA/PESA, embryo transfer, egg freezing, and chromosome screening, as well as surrogacy and ancillary caring services. The company was founded in 2010 and is based in Central, Hong Kong.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.